公开(公告)号：US12011479B2

公开(公告)日：2024-06-18

申请号：US17518268

申请日：2021-11-03

Applicant: Mayo Foundation for Medical Education and Research

Inventor： Miguel A. Munoz Alia ,  Stephen James Russell

IPC: C12N7/00 ,  A61K39/165 ,  C12N7/01 ,  C12N15/00 ,  C12N15/86 ,  C12N15/861 ,  A61K39/00

CPC classification number: A61K39/165 ,  C12N7/00 ,  A61K2039/5256 ,  A61K2039/55 ,  C12N2710/10021 ,  C12N2760/18421 ,  C12N2760/18422 ,  C12N2760/18434

Abstract: This document relates to methods and materials for making and using viruses (e.g., measles viruses or adenoviruses) having a reduced susceptibility to antibody neutralization (e.g., antibody neutralization by serum from measles virus vaccines). For example, recombinant morbilliviruses (e.g., recombinant measles viruses) having a modified H gene and a modified F gene, as well as methods of using a recombinant virus are provided.

公开(公告)号：US11975065B2

公开(公告)日：2024-05-07

申请号：US17518268

申请日：2021-11-03

Applicant: Mayo Foundation for Medical Education and Research

Inventor： Miguel A. Munoz Alia ,  Stephen James Russell

IPC: C12N7/00 ,  A61K39/165 ,  C12N7/01 ,  C12N15/00 ,  C12N15/86 ,  C12N15/861 ,  A61K39/00

CPC classification number: A61K39/165 ,  C12N7/00 ,  A61K2039/5256 ,  A61K2039/55 ,  C12N2710/10021 ,  C12N2760/18421 ,  C12N2760/18422 ,  C12N2760/18434

Abstract: This document relates to methods and materials for making and using viruses (e.g., measles viruses or adenoviruses) having a reduced susceptibility to antibody neutralization (e.g., antibody neutralization by serum from measles virus vaccines). For example, recombinant morbilliviruses (e.g., recombinant measles viruses) having a modified H gene and a modified F gene, as well as methods of using a recombinant virus are provided.

公开(公告)号：US20180228888A1

公开(公告)日：2018-08-16

申请号：US15580764

申请日：2016-06-10

Applicant: INSTITUT PASTEUR ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Inventor： Nicolas Robert Xavier ESCRIOU ,  Frederic TANGY ,  Ho Hong Hai VO

IPC: A61K39/145

CPC classification number: A61K39/145 ,  A61K39/12 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/55 ,  A61K2039/70 ,  C12N2760/16122 ,  C12N2760/16123 ,  C12N2760/16134 ,  C12N2760/18434 ,  C12N2760/18441

Abstract: The invention relates to an active ingredient which is a live attenuated recombinant measles virus expressing influenza A virus antigen(s) and to its use in the elicitation of immunity, in particular protective immunity and advantageously broad-spectrum protective immunity against influenza A virus. In particular, the influenza A virus is selected among epidemic seasonal viruses and/or endemic viruses circulating in the human population and advantageously encompasses a pandemic virus such as H1N1v.

公开(公告)号：US09895321B2

公开(公告)日：2018-02-20

申请号：US13642878

申请日：2011-04-22

Applicant: Robert E. Sievers ,  Stephen P. Cape ,  David McAdams ,  J'aime Manion ,  Pankaj Pathak

Inventor： Robert E. Sievers ,  Stephen P. Cape ,  David McAdams ,  J'aime Manion ,  Pankaj Pathak

IPC: A61K39/395 ,  A61K31/047 ,  A61K9/00 ,  A61K9/16 ,  A61K9/51 ,  A61K39/12 ,  A61K39/165 ,  A61K45/06 ,  A61K39/00

CPC classification number: A61K31/047 ,  A61K9/0056 ,  A61K9/0075 ,  A61K9/1647 ,  A61K9/1688 ,  A61K9/1694 ,  A61K9/5153 ,  A61K9/5192 ,  A61K39/12 ,  A61K39/165 ,  A61K45/06 ,  A61K2039/54 ,  A61K2039/542 ,  A61K2039/543 ,  A61K2039/544 ,  A61K2039/60 ,  C12N2760/18434 ,  A61K2300/00

Abstract: Methods and products for treating and/or delaying onset of dysplastic lesions, and wafers for oral administration employ dry powder compositions including myo-inositol. Methods for administering a vaccine for a virus or bacteria to an individual comprising administering a first portion of the vaccine to the individual via one route and administering a second portion via a second, different route. In a specific embodiment, the first route is sublingually. Vaccines are provided in the form of dry powder compositions comprising a combination of nanoparticles and microparticles, or in the form of a wafer which dissolves in water at room temperature in less than about one minute. Storage stable unit dosages of a vaccine are provided by individually packaging individual unit dosages of a dry powder composition comprising the vaccine and a carrier in blister compartments formed of gas and moisture resistant material.

公开(公告)号：US09889193B2

公开(公告)日：2018-02-13

申请号：US14762559

申请日：2014-01-20

Applicant: INSTITUT PASTEUR ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE ,  UNIVERSITE DE NANTES

Inventor： Frédéric Tangy ,  Marc Gregoire ,  Jean-François Fonteneau ,  Jean-Baptiste Guillerme ,  Chantal Combredet

IPC: A61K39/165 ,  A61K35/768 ,  C12N7/00 ,  A61K35/15 ,  A61K39/00

CPC classification number: A61K39/165 ,  A61K35/15 ,  A61K35/768 ,  A61K2039/5154 ,  A61K2039/5254 ,  C12N7/00 ,  C12N2760/18421 ,  C12N2760/18432 ,  C12N2760/18434 ,  C12N2760/18462

Abstract: The invention relates to a genetically modified infectious measles virus derived from a live-attenuated measles virus strain, in which the gene encoding the viral accessory C protein has been knocked out (MV-deltaC). It concerns in particular the use of said genetically modified infectious MV-deltaC in the treatment of malignant tumor or cancer conditions, and for the preparation of agents or compositions for such treatment.

公开(公告)号：US20170258889A1

公开(公告)日：2017-09-14

申请号：US15492363

申请日：2017-04-20

Applicant: Trustees of Tufts College

Inventor： David L. Kaplan ,  Fiorenzo G. Omenetto

IPC: A61K39/20 ,  A61K39/00 ,  A61K39/02 ,  A61K39/04 ,  A61K39/08 ,  A61K39/09 ,  A61K39/095 ,  A61K39/12 ,  A61K39/165 ,  A61K47/42 ,  A61K47/46 ,  A61K9/00 ,  A61K9/06 ,  A61K9/14 ,  A61K9/19 ,  A61K9/50 ,  A61K9/70 ,  B82Y5/00 ,  A61K38/00

CPC classification number: A61K39/20 ,  A61K9/0019 ,  A61K9/06 ,  A61K9/146 ,  A61K9/19 ,  A61K9/5026 ,  A61K9/5063 ,  A61K9/7007 ,  A61K38/00 ,  A61K39/0015 ,  A61K39/02 ,  A61K39/04 ,  A61K39/08 ,  A61K39/092 ,  A61K39/095 ,  A61K39/099 ,  A61K39/12 ,  A61K39/165 ,  A61K47/42 ,  A61K47/46 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/6031 ,  A61K2039/622 ,  A61K2039/64 ,  A61K2039/70 ,  B82Y5/00 ,  C12N2760/18434 ,  C12N2760/18734 ,  C12N2770/36234 ,  Y02A50/388 ,  Y02A50/39 ,  Y02A50/466 ,  Y02A50/484

Abstract: Provided herein are methods and compositions for stabilization of active agents. The active agents are distributed, mixed or embedded in a silk fibroin matrix, thereby retaining the bioactivity of the active agents upon storage and/or transportation. In some embodiments, the storage-stable vaccine-silk compositions are also provided herein.

公开(公告)号：US20170157036A1

公开(公告)日：2017-06-08

申请号：US15350718

申请日：2016-11-14

Applicant: THE CORPORATION OF MERCER UNIVERSITY

Inventor： Martin J. D'SOUZA

IPC: A61K9/00 ,  A61K39/095 ,  A61K39/00 ,  C12N7/00 ,  B29C41/04 ,  A61K39/12 ,  A61K39/155 ,  A61K35/39 ,  A61M37/00 ,  B29C41/00 ,  A61K9/16 ,  A61K39/145

CPC classification number: A61K9/0021 ,  A61K9/1652 ,  A61K31/727 ,  A61K35/39 ,  A61K39/0008 ,  A61K39/0011 ,  A61K39/095 ,  A61K39/12 ,  A61K39/145 ,  A61K39/155 ,  A61K39/165 ,  A61K39/39 ,  A61K48/00 ,  A61K2039/52 ,  A61K2039/525 ,  A61K2039/5252 ,  A61K2039/54 ,  A61K2039/55555 ,  A61K2039/55566 ,  A61K2039/55594 ,  A61K2039/57 ,  A61M37/0015 ,  A61M2037/003 ,  A61M2037/0061 ,  B29C33/42 ,  B29C39/023 ,  B29C41/003 ,  B29C41/04 ,  B29K2029/04 ,  B29K2105/0035 ,  B29L2031/7544 ,  B29L2031/756 ,  C12N5/0677 ,  C12N7/00 ,  C12N15/88 ,  C12N2533/72 ,  C12N2533/74 ,  C12N2710/20023 ,  C12N2710/20034 ,  C12N2760/16034 ,  C12N2760/16134 ,  C12N2760/18434 ,  C12N2760/18534

Abstract: A transdermal delivery system of microneedles containing a bioactive material, comprising at least one layer of a support material; at least one biodegradable needle associated with the support material, each needle comprising at least one biodegradable polymer and at least one sugar, wherein each biodegradable needle is hollow and is adapted to retain a bioactive material.

公开(公告)号：US20170151319A1

公开(公告)日：2017-06-01

申请号：US15431329

申请日：2017-02-13

Applicant: Alexandre Eduardo Nowill

Inventor： Alexandre Eduardo Nowill

IPC: A61K39/04 ,  A61K39/09 ,  A61K39/00 ,  A61K39/112 ,  A61K39/12 ,  C12N7/00 ,  A61K39/108 ,  A61K39/095 ,  A61K39/165 ,  A61K39/02 ,  A61K39/13 ,  A61K39/25 ,  A61K39/285 ,  A61K39/245 ,  A61K39/05 ,  A61K39/29 ,  A61K39/102 ,  A61K39/085

CPC classification number: A61K39/04 ,  A61K9/0019 ,  A61K9/08 ,  A61K39/0002 ,  A61K39/025 ,  A61K39/0258 ,  A61K39/0275 ,  A61K39/05 ,  A61K39/085 ,  A61K39/092 ,  A61K39/095 ,  A61K39/099 ,  A61K39/102 ,  A61K39/105 ,  A61K39/12 ,  A61K39/13 ,  A61K39/165 ,  A61K39/245 ,  A61K39/25 ,  A61K39/285 ,  A61K39/292 ,  A61K45/06 ,  A61K47/10 ,  A61K2039/521 ,  A61K2039/5254 ,  A61K2039/70 ,  C12N2710/16634 ,  C12N2710/16734 ,  C12N2710/24134 ,  C12N2730/10134 ,  C12N2760/18434 ,  C12N2770/24134 ,  C12N2770/32334 ,  C12N2770/36234 ,  Y02A50/474 ,  Y02A50/482

Abstract: The present invention refers to pharmaceutical products comprising immunogenic compositions for modulating the immune system, which comprise a therapeutically effective amount of a Immunological Response Shifter (IRS) comprising two or more immunoactive antigenic agents presenting pathogen-associated molecular patterns (PAMPS) and/or danger associated molecular patterns (DAMPS) and/or Stress Response Signals (SRS), in association with an antibiotic and one or more physiologically acceptable carriers, excipients, diluents or solvents. IN other embodiments, the present invention refers to methods to treat severe bacterial infections, sepsis and modulating the immune system.

公开(公告)号：US09308250B2

公开(公告)日：2016-04-12

申请号：US14486578

申请日：2014-09-15

Applicant: CADILA HEALTHCARE LIMITED

Inventor： Reinhard Glueck ,  Agata Fazio ,  Viviana Gianino ,  Martin A. Billeter

IPC: C12N15/00 ,  A61K39/165 ,  A61K38/20 ,  A61K39/00 ,  A61K39/015 ,  A61K39/12 ,  C12N7/00 ,  A61K35/13

CPC classification number: A61K39/165 ,  A61K35/13 ,  A61K38/2013 ,  A61K39/0015 ,  A61K39/015 ,  A61K39/12 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/55566 ,  A61K2039/55588 ,  A61K2039/575 ,  A61K2039/70 ,  C12N7/00 ,  C12N2760/18421 ,  C12N2760/18434 ,  C12N2760/18442 ,  C12N2760/18443 ,  Y02A50/412

Abstract: A combined measles-malaria vaccine containing different attenuated recombinant measles-malaria vectors comprising a heterologous nucleic acid encoding several Plasmodium falciparum antigens is described. Preferably, it relates to viral vectors that comprise nucleic acids encoding the circumsporozoite (CS) protein of P. falciparum, the merozoite surface protein 1 (MSP-1) of P. falciparum, and its derivatives (p-42; p-83-30-38) in its glycosylated and secreted forms, and apical membrane antigen1 (AMA1) of P. falciparum, in its anchored or secreted form. The viral vector stems from an attenuated measles virus, based on a strain that is used as a vaccine and is efficient in delivering the gene of interest and that binds to and infects the relevant immune cells efficiently.

公开(公告)号：US20160040187A1

公开(公告)日：2016-02-11

申请号：US14667326

申请日：2015-03-24

Applicant: Frederic TANGY ,  Clarisse LORIN ,  Lucile MOLLET ,  Frederic DELEBECQUE

Inventor： Frederic TANGY ,  Clarisse LORIN ,  Lucile MOLLET ,  Frederic DELEBECQUE

IPC: C12N15/86 ,  A61K39/21 ,  A61K39/12 ,  A61K39/165 ,  C12N7/00

CPC classification number: C12N15/86 ,  A61K39/12 ,  A61K39/165 ,  A61K39/21 ,  A61K47/6901 ,  A61K2039/5256 ,  C07K14/005 ,  C12N7/00 ,  C12N2740/16022 ,  C12N2740/16122 ,  C12N2760/18421 ,  C12N2760/18422 ,  C12N2760/18434 ,  C12N2760/18443 ,  C12N2760/18452 ,  C12N2770/24122 ,  Y02A50/388 ,  Y02A50/394

Abstract: The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus, said recombinant measles virus being capable of eliciting a humoral and/or cellular immune response against measles virus or against said RNA virus or against both measles virus and against said RNA virus. It also relates to the use of said recombinant measles virus for the preparation of immunogenic composition.